3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑
中文名称 | 3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 |
---|---|
中文同义词 | 3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑;ATG-010;3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 1级;1-(4-(5-(4-氯苯基)-4-(嘧啶-4-基)-1H-吡唑-3-基)哌啶-1-基)-2-羟基乙酮;SD-06-1游离;SD-06,P38Α MAPK 的二芳基吡唑抑制剂 |
英文名称 | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole |
英文同义词 | 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole;SD-06;SD-06-1;1-(4-(5-(4-Chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-hydroxyethanone;SD 0006;SD-06;SD 06;SD06;SD 0006(SD-06);CS-2591 |
CAS号 | 271576-80-8 |
分子式 | C20H20ClN5O2 |
分子量 | 397.86 |
EINECS号 | |
相关类别 | MAPK |
Mol文件 | 271576-80-8.mol |
结构式 |
3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 性质
沸点 | 652.6±55.0 °C(Predicted) |
---|---|
密度 | 1.367 |
储存条件 | 2-8°C |
溶解度 | DMSO:50 mg/mL(125.67 mM;需要超声波) |
形态 | 粉末 |
酸度系数(pKa) | 9.39±0.50(Predicted) |
IC50: 110 nM (p38 MAPK).
SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate.
SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.
SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling.
Animal Model: | 8- to 12-week-old DBA/1 mice. |
Dosage: | 3.75, 7.5 and 15 mg/kg. |
Administration: | Orally twice daily. |
Result: | Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density. |
安全信息
海关编码 | 2924297099 |
---|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/01/25 | HY-11087 | SD 0006 | 1 mg | 500元 | |
2024/01/25 | HY-11087 | 3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 SD 0006 | 271576-80-8 | 5mg | 1100元 |